Gestational Diabetes Mellitus in PregnancyNCT03961542
Effects of Chewing Gum on Glycaemic Control in Women With Gestational Diabetes
A study testing Chewing in people with Gestational Diabetes Mellitus in Pregnancy, run by Medical University of Vienna at 1 site in Austria.
Trial summary
This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Gestational Diabetes Mellitus in Pregnancy
- What is being tested?
- Chewing
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 74 participants
- Where
- 1 siteAustria
- Study dates
- 22 Dec 2017to 10 Dec 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- -
Who cannot join
- Preconceptional overt diabetes (such as type 1 or type 2 diabetes)
- History of bariatric surgery or surgeries that induce malabsorption
- HIV- or hepatitis infection
- Decreased liver or kidney function (before pregnancy)
- history of malignant disorders
- Abuse of toxic substances
Show all 10Show fewer
- Use of systemic steroids
- Active smoking status during pregnancy
- Multiple pregnancy
- Ovulatory drugs and in-vitro fertilisation
Trial locations and contacts
1 site in 1 country.
About this study
This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study.
Differences in fasting glucose and longitudinal changes over the study period should be additionally examined.
Read the detailed description
Study design and participants This study is designed as an open-label, mono-centre randomized controlled trial with two parallel groups including a total of 74 female patients with recent diagnosis of GDM. Diagnosis of GDM is made in accordance with the IADPSG criteria between 24+0 and 27+6 weeks of gestation [IADPSG 2010]. All pregnant females (aged
between 18 and 45 years) will be recruited consecutively among women visiting our pregnancy outpatient department (Department of Obstetrics and Gynecology, Division of Obstetrics and fetomaternal Medicine, Medical University of Vienna).
Exclusion criteria
- Preconceptional overt diabetes (such as type 1 or type 2 diabetes)
- History of bariatric surgery or surgeries that induce malabsorption
- HIV- or hepatitis infection
- Decreased liver or kidney function (before pregnancy)
- history of malignant disorders
- Abuse of toxic substances
- Use of systemic steroids
- Multiple pregnancy
Treatment and Interventions Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement
(fasting as well as 1h after starting each meal). Capillary blood glucose profiles are re- evaluated seven days after starting the blood glucose monitoring.
Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
Randomisation Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m2); ii. overweight (BMI 26 - 30 kg/m2); iii. obesity (BMI and above 30 kg/m2).
Medical history and baseline examination A broad risk evaluation will be performed in participating females at the initial contact (between 24+0 and 32+0 weeks of gestation) including: evaluation of maternal age, parity, history of GDM, detailed family history, ethnicity, preconceptional diseases, use of ovulation drugs, obstetric history. Moreover, an evaluation of preconceptional weight and BMI as well as measurement of blood pressure will be performed.
Assessment of dietary patterns Dietary patterns will be assessed at baseline (visit 1) by using a published and validated Food-Frequency-Questionnaire (FFQ) proposed by the German Robert Koch Institute [Haftenberg 2010]. It was also previously used for the German DEGS project (www.degs-studie.de). Information from the FFQ will be analyzed quantitatively or summarized by eating scores proposed in the literature (such as the Healthy Eating Index 2010 or Alternate Healthy Eating Index 2010) reflecting diet quality based on actual guidelines [Guenther 2013, Chiuve 2012]. In addition all patients will be advised to conduct a nutritional protocol for seven days. D. End Points
The three primary end points of this study are the averages (arithmetic mean values) of five days 1h postprandial capillary blood glucose measurements: after breakfast (primary end point 1), lunch (primary end point 2) and dinner (primary end point 3).
Secondary end points are fasting glucose concentrations and longitudinal changes (i.e.
assessment of group by time interactions in fasting and postprandial glucose trajectories) as well as changes in dietary patterns.
- Statistical Analysis
Sample size With a sample size of n=35 subjects per group we are able to detect a mean difference of 8 mg/dl in postprandial glucose levels with a power of 81% and a type 1 error of α=0.016 for a two-sided unpaired student's t-test, providing a standard deviation of 10 mg/dl in accordance with [Landon 2009]. In order to achieve a 95% coverage probability, the Bonferroni correction will be used to adjust for multiple testing (three primary outcomes). Considering a drop-out rate of 5% n=74 cases are required for this study. A sample size review and adaptation is planned after 50% of the subjects have been investigated.
Analysis Plan Categorical variables will be summarized by counts and percentages; continuous variables data are summarized by means and standard deviations (SD) or by median and interquartile range in the case of strong deviations from the normal distribution.
Statistical comparison of continuous parameters (e.g. postprandial or fasting glucose concentrations) will be performed by the two-sample t-test or nonparametric
approaches (e.g. the Brunner-Munzel test), respectively. An adjustment for demographic variables (such as age) will be performed in case of significant group differences using analysis of covariance (ANCOVA) or by the proportional odds model, if the normality assumption is violated. Linear mixed effects models will be used to assess longitudinal changes of parameters of interest (i.e. fasting and postprandial glucose). Interaction terms are included in the longitudinal models to assess group differences and variable transformations (e.g. logarithmic or square root transformation) are used if necessary. A two-sided p-value ≤0.05 is considered statistically significant. Using the Bonferroni correction for multiple statistical testing (three hypotheses) this results in a 98.33% confidence interval to achieve a 95% simultaneous coverage probability. All analyses will be performed by using the statistic software R and contributing packages [R Core Team 2016].
- Being tested
- Chewing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ChewingOther
Also called chewing, gum, blood glucose
Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Experimental | This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study.
Differences in fasting glucose and longitudinal changes over the study period should be additionally examined. Receives: Other: Chewing |
| Control Group | No intervention | Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m²); ii. overweight (BMI 26 - 30 kg/m²); iii. obesity (BMI and above 30 kg/m²). |
What is being measured
The primary outcome is the main question the study is designed to answer.
blood glucose measurements after with or without chewing
1hour postprandial capillary blood glucose measurements
Measured: for one week (7 Days) after breakfast, lunch and dinner
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 May 2019
- Study start22 Dec 2017
- Primary completion30 Nov 2018
- Study completion10 Dec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gestational Diabetes Mellitus in PregnancyStudies of the same condition, open and under way.
- More trials run by Medical University of ViennaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 74 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Christian Göbl, Medical University of Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03961542
- Sponsor's protocol ID
- 20171218
- Status last verified
- May 2019
- First submitted
- 20 Jan 2019
- Last updated
- 23 May 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Yerlikaya-Schatten G, Trimmal L, Rosicky I, Husslein P, Schatten C, Eppel D, Eppel W, Tura A, Gobl CS. Effects of gum chewing on glycaemic control in women with gestational diabetes mellitus: A randomized controlled trial. Impact of chewing on hyperglycaemia in women with GDM. Eur J Obstet Gynecol Reprod Biol. 2020 Apr;247:61-65. doi: 10.1016/j.ejogrb.2020.02.003. Epub 2020 Feb 9.
PubMed 32070847
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Chewing Gum on Glycaemic Control in Women With Gestational Diabetes
- ClinicalTrials.gov ID
- NCT03961542
- Acronym / sponsor ID
- 20171218
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 74 participants (actual)
- Lead sponsor
- Medical University of ViennaUniversity, hospital or other
- Study start
- 22 Dec 2017 (actual)
- Primary completion
- 30 Nov 2018 (actual)
- Study completion
- 10 Dec 2018 (actual)
- First posted
- 23 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study.
Differences in fasting glucose and longitudinal changes over the study period should be additionally examined.
Detailed description
Study design and participants This study is designed as an open-label, mono-centre randomized controlled trial with two parallel groups including a total of 74 female patients with recent diagnosis of GDM. Diagnosis of GDM is made in accordance with the IADPSG criteria between 24+0 and 27+6 weeks of gestation [IADPSG 2010]. All pregnant females (aged
between 18 and 45 years) will be recruited consecutively among women visiting our pregnancy outpatient department (Department of Obstetrics and Gynecology, Division of Obstetrics and fetomaternal Medicine, Medical University of Vienna).
Exclusion criteria
- Preconceptional overt diabetes (such as type 1 or type 2 diabetes)
- History of bariatric surgery or surgeries that induce malabsorption
- HIV- or hepatitis infection
- Decreased liver or kidney function (before pregnancy)
- history of malignant disorders
- Abuse of toxic substances
- Use of systemic steroids
- Multiple pregnancy
Treatment and Interventions Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement
(fasting as well as 1h after starting each meal). Capillary blood glucose profiles are re- evaluated seven days after starting the blood glucose monitoring.
Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
Randomisation Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m2); ii. overweight (BMI 26 - 30 kg/m2); iii. obesity (BMI and above 30 kg/m2).
Medical history and baseline examination A broad risk evaluation will be performed in participating females at the initial contact (between 24+0 and 32+0 weeks of gestation) including: evaluation of maternal age, parity, history of GDM, detailed family history, ethnicity, preconceptional diseases, use of ovulation drugs, obstetric history. Moreover, an evaluation of preconceptional weight and BMI as well as measurement of blood pressure will be performed.
Assessment of dietary patterns Dietary patterns will be assessed at baseline (visit 1) by using a published and validated Food-Frequency-Questionnaire (FFQ) proposed by the German Robert Koch Institute [Haftenberg 2010]. It was also previously used for the German DEGS project (www.degs-studie.de). Information from the FFQ will be analyzed quantitatively or summarized by eating scores proposed in the literature (such as the Healthy Eating Index 2010 or Alternate Healthy Eating Index 2010) reflecting diet quality based on actual guidelines [Guenther 2013, Chiuve 2012]. In addition all patients will be advised to conduct a nutritional protocol for seven days. D. End Points
The three primary end points of this study are the averages (arithmetic mean values) of five days 1h postprandial capillary blood glucose measurements: after breakfast (primary end point 1), lunch (primary end point 2) and dinner (primary end point 3).
Secondary end points are fasting glucose concentrations and longitudinal changes (i.e.
assessment of group by time interactions in fasting and postprandial glucose trajectories) as well as changes in dietary patterns.
- Statistical Analysis
Sample size With a sample size of n=35 subjects per group we are able to detect a mean difference of 8 mg/dl in postprandial glucose levels with a power of 81% and a type 1 error of α=0.016 for a two-sided unpaired student's t-test, providing a standard deviation of 10 mg/dl in accordance with [Landon 2009]. In order to achieve a 95% coverage probability, the Bonferroni correction will be used to adjust for multiple testing (three primary outcomes). Considering a drop-out rate of 5% n=74 cases are required for this study. A sample size review and adaptation is planned after 50% of the subjects have been investigated.
Analysis Plan Categorical variables will be summarized by counts and percentages; continuous variables data are summarized by means and standard deviations (SD) or by median and interquartile range in the case of strong deviations from the normal distribution.
Statistical comparison of continuous parameters (e.g. postprandial or fasting glucose concentrations) will be performed by the two-sample t-test or nonparametric
approaches (e.g. the Brunner-Munzel test), respectively. An adjustment for demographic variables (such as age) will be performed in case of significant group differences using analysis of covariance (ANCOVA) or by the proportional odds model, if the normality assumption is violated. Linear mixed effects models will be used to assess longitudinal changes of parameters of interest (i.e. fasting and postprandial glucose). Interaction terms are included in the longitudinal models to assess group differences and variable transformations (e.g. logarithmic or square root transformation) are used if necessary. A two-sided p-value ≤0.05 is considered statistically significant. Using the Bonferroni correction for multiple statistical testing (three hypotheses) this results in a 98.33% confidence interval to achieve a 95% simultaneous coverage probability. All analyses will be performed by using the statistic software R and contributing packages [R Core Team 2016].
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Experimental | Other: ChewingThis study aims to assess the impact of enhanced chewing on glycaemic control in females with newly diagnosed GDM. It is hypothesised, that a fixed amount of gum chewed for 20 minutes before starting each meal could improve hyperglycaemia. The impact of chewing on postprandial capillary blood glucose (measured at one hour after breakfast, lunch and dinner) is determined as the primary outcome of this study. Differences in fasting glucose and longitudinal changes over the study period should be additionally examined. |
| Control Group | No intervention | –Participants will be randomized to either treatment (chewing gum) or control group (routine care) in a 1:1 ratio. The minimisation method [Pocock 1975] will be used to minimize the imbalance between the groups according to the preconceptional overweight/obesity status with three strata: i. normal weight (i.e. BMI below 25 kg/m²); ii. overweight (BMI 26 - 30 kg/m²); iii. obesity (BMI and above 30 kg/m²). |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- -
Key exclusion criteria (10 listed)
- Preconceptional overt diabetes (such as type 1 or type 2 diabetes)
- History of bariatric surgery or surgeries that induce malabsorption
- HIV- or hepatitis infection
- Decreased liver or kidney function (before pregnancy)
- history of malignant disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ChewingAlso: chewing, gum, blood glucoseEligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2). | Other | Intervention Group |
Primary outcome
blood glucose measurements after with or without chewing
Time frame: for one week (7 Days) after breakfast, lunch and dinner
1hour postprandial capillary blood glucose measurements
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2019.
- Derived from this study: PubMed 32070847Yerlikaya-Schatten G, Trimmal L, Rosicky I, Husslein P, Schatten C, Eppel D, Eppel W, Tura A, Gobl CS. Effects of gum chewing on glycaemic control in women with gestational diabetes mellitus: A randomized controlled trial. Impact of chewing on hyperglycaemia in women with GDM. Eur J Obstet Gynecol Reprod Biol. 2020 Apr;247:61-65. doi: 10.1016/j.ejogrb.2020.02.003. Epub 2020 Feb 9.
- Individual participant dataSharing planned: No
Related trials for Gestational Diabetes Mellitus in Pregnancy
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Not yet recruitingObservational study
Ultrasound Assessment Of Gastric Volume In Pregnant Women Undergoing Elective Cesarean Section
Gestational Diabetes Mellitus (GDM), Obstetric Anesthesia
Active, not recruitingPhase 2
Effectiveness Study of a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestational Diabetes
Weight Loss, Gestational Diabetes Mellitus in Pregnancy
Not yet recruiting
STRONG: SMART Trial
Gestational Diabetes Mellitus (GDM)
Not yet recruiting
A Study to Lower Blood Pressure One Year After Childbirth in Women Who Had Preeclampsia
Adverse Pregnancy Outcomes, Cardiovascular Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Chewing in people with Gestational Diabetes Mellitus in Pregnancy, run by Medical University of Vienna at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 May 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
blood glucose measurements after with or without chewing (time frame: for one week (7 Days) after breakfast, lunch and dinner). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03961542, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2019.